115 related articles for article (PubMed ID: 29522793)
1. Botulinum toxin type A affects the transcriptome of cell cultures derived from muscle biopsies of controls and spastic patients.
Zanotti S; Kapetis D; Gibertini S; Salerno F; Ciusani E; Colombo C; Gronchi A; Morandi L; Mantegazza R; Molteni F; Mora M
Toxicol In Vitro; 2018 Aug; 50():124-136. PubMed ID: 29522793
[TBL] [Abstract][Full Text] [Related]
2. Use of gait parameters to predict the effectiveness of botulinum toxin injection in the spastic rectus femoris muscle of stroke patients with stiff knee gait.
Roche N; Boudarham J; Hardy A; Bonnyaud C; Bensmail B
Eur J Phys Rehabil Med; 2015 Aug; 51(4):361-70. PubMed ID: 25213306
[TBL] [Abstract][Full Text] [Related]
3. Skeletal muscle atrophy induced by intramuscular repeated dose of botulinum toxin type A in rats.
Choi WH; Song CW; Kim YB; Ha CS; Yang GH; Woo HD; Jung HH; Koh WS
Drug Chem Toxicol; 2007; 30(3):217-27. PubMed ID: 17613007
[TBL] [Abstract][Full Text] [Related]
4. Do skeletal muscle properties recover following repeat onabotulinum toxin A injections?
Fortuna R; Horisberger M; Vaz MA; Herzog W
J Biomech; 2013 Sep; 46(14):2426-33. PubMed ID: 23953503
[TBL] [Abstract][Full Text] [Related]
5. Neurophysiological changes induced by the botulinum toxin type A injection in children with cerebral palsy.
Frascarelli F; Di Rosa G; Bisozzi E; Castelli E; Santilli V
Eur J Paediatr Neurol; 2011 Jan; 15(1):59-64. PubMed ID: 20493744
[TBL] [Abstract][Full Text] [Related]
6. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
Wissel J; Entner T
Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
[TBL] [Abstract][Full Text] [Related]
7. A clinically relevant BTX-A injection protocol leads to persistent weakness, contractile material loss, and an altered mRNA expression phenotype in rabbit quadriceps muscles.
Fortuna R; Vaz MA; Sawatsky A; Hart DA; Herzog W
J Biomech; 2015 Jul; 48(10):1700-6. PubMed ID: 26087882
[TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin for hereditary spastic paraplegia: effects on motor and non-motor manifestations.
Servelhere KR; Faber I; Martinez A; Nickel R; Moro A; Germiniani FMB; Moscovich M; Blume TR; Munhoz RP; Teive HAG; França MC
Arq Neuropsiquiatr; 2018 Mar; 76(3):183-188. PubMed ID: 29809239
[TBL] [Abstract][Full Text] [Related]
9. Treatment with Botulinum toxin A in a total population of children with cerebral palsy - a retrospective cohort registry study.
Franzén M; Hägglund G; Alriksson-Schmidt A
BMC Musculoskelet Disord; 2017 Dec; 18(1):520. PubMed ID: 29228927
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin-A with and without rehabilitation for the treatment of spastic cerebral palsy.
Jianjun L; Shurong J; Weihong W; Yan Z; Fanyong Z; Nanling L
J Int Med Res; 2013 Jun; 41(3):636-41. PubMed ID: 23696596
[TBL] [Abstract][Full Text] [Related]
11. A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot.
Mancini F; Sandrini G; Moglia A; Nappi G; Pacchetti C
Neurol Sci; 2005 Apr; 26(1):26-31. PubMed ID: 15877184
[TBL] [Abstract][Full Text] [Related]
12. Effect of Dual Therapy with Botulinum Toxin A Injection and Electromyography-controlled Functional Electrical Stimulation on Active Function in the Spastic Paretic Hand.
Tsuchiya M; Morita A; Hara Y
J Nippon Med Sch; 2016; 83(1):15-23. PubMed ID: 26960584
[TBL] [Abstract][Full Text] [Related]
13. Changes in contractile properties of muscles receiving repeat injections of botulinum toxin (Botox).
Fortuna R; Vaz MA; Youssef AR; Longino D; Herzog W
J Biomech; 2011 Jan; 44(1):39-44. PubMed ID: 20828699
[TBL] [Abstract][Full Text] [Related]
14. Age-related botulinum toxin effects on muscle fiber conduction velocity in non-injected muscles.
Lange F; van Weerden TW; van der Hoeven JH
Clin Neurophysiol; 2007 Nov; 118(11):2398-403. PubMed ID: 17897878
[TBL] [Abstract][Full Text] [Related]
15. Physiological effects of botulinum toxin in spasticity.
Gracies JM
Mov Disord; 2004 Mar; 19 Suppl 8():S120-8. PubMed ID: 15027064
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of incobotulinum toxin type A (NT 201-Xeomin) for the treatment of post-stroke lower limb spasticity: a prospective open-label study.
Santamato A; Micello MF; Panza F; Fortunato F; Pilotto A; Giustini A; Testa A; Fiore P; Ranieri M; Spidalieri R
Eur J Phys Rehabil Med; 2013 Aug; 49(4):483-9. PubMed ID: 23480980
[TBL] [Abstract][Full Text] [Related]
17. The use of botulinum toxin for spasticity after spinal cord injury.
Marciniak C; Rader L; Gagnon C
Am J Phys Med Rehabil; 2008 Apr; 87(4):312-7; quiz 318-20, 329. PubMed ID: 18356622
[TBL] [Abstract][Full Text] [Related]
18. Management of stroke patients submitted to botulinum toxin type A therapy: a Delphi survey of an Italian expert panel of specialist injectors.
Franceschini M; Iocco M; Molteni F; Santamato A; Smania N;
Eur J Phys Rehabil Med; 2014 Oct; 50(5):525-33. PubMed ID: 24963604
[TBL] [Abstract][Full Text] [Related]
19. Cortical somatosensory evoked potentials and spasticity assessment after botulinum toxin type A injection in children with cerebral palsy.
Boćkowski L; Okurowska-Zawada B; Sobaniec W; Kułak W; Sendrowski K
Adv Med Sci; 2007; 52 Suppl 1():171-5. PubMed ID: 18229658
[TBL] [Abstract][Full Text] [Related]
20. Is an instrumented spasticity assessment an improvement over clinical spasticity scales in assessing and predicting the response to integrated botulinum toxin type a treatment in children with cerebral palsy?
Bar-On L; Van Campenhout A; Desloovere K; Aertbeliën E; Huenaerts C; Vandendoorent B; Nieuwenhuys A; Molenaers G
Arch Phys Med Rehabil; 2014 Mar; 95(3):515-23. PubMed ID: 23994052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
